RecruitingAcute Cannabis-induced CNS Depression
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
Eligible age
All ages
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.
Sponsor: Anebulo Pharmaceuticals
You may qualify if…
- ✓ 1. Inclusion Criteria:The patient is younger than 18 years old.
- ✓ 2. The patient visits the ED with signs and symptoms of suspected acute cannabis-induced CNS depression, as evidenced by the patient suffering from clinically significant CNS depression combined with the following criteria:
- ✓ a) Exposure to cannabis or cannabis-derived products, or other products containing any CB1 agonist (such as Δ8-THC, HHC) within the last 12 hours, confirmed through one or more of the following: i. Positive toxicology testing, or ii. Other clinical evidence, such as reliable collateral history (e.g., from caregivers, EMS personnel, or witnesses), physical evidence (e.g., product packaging), or a consistent self-report.
- ✓ AND EITHER
- ✓ b) Symptoms are associated with cannabis exposure and developed during, or shortly after, cannabis exposure;
- ✓ OR
- ✓ c) In the judgment of investigator or designated clinician, the presentation includes symptoms consistent with acute cannabis-induced CNS depression (e.g. respiratory rate depression, increased sedative effects).
- ✓ 3. Blood samples are taken as part of routine clinical procedures, or the patient has an IV line through which blood can be taken.
You may not qualify if…
- ✕ A potential patient who meets any of the following criteria will be excluded from participation in this study:
- ✕ 1. Anything that, in the opinion of the PI, would place the patient at increased risk or preclude the patient's compliance with or completion of the study.
- ✕ 2. Patient is presenting with signs or symptoms that are better explained by another medical condition or mental disorder, exposure to a drug other than cannabis, and, at the PI's discretion, are not induced by acute cannabis exposure.
- ✕ 3. Patient presenting with cannabis use disorder (CUD), cannabis hyperemesis syndrome (CHS) or cannabis withdrawal syndrome (CWS)
- ✕ 4. Patients who are brought in by law enforcement, i.e., cannabis intoxication associated with a vehicle accident (driving under the influence).
Where it's recruiting
Source: ClinicalTrials.gov · NCT06017622 · last updated 2026-07-30